Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Overview of Interstitial Cystitis for the Primary Care Physician WVU WOMENS HEALTH CURRICULUM – Revisions 9/2008 Stanley Zaslau, MD, MBA, FACS Program Director & Associate Professor Section of Urology West Virginia University Objectives • In this lecture, participants will learn: – Incidence, epidemiology and pathogenesis of Interstitial Cystitis (IC) • Understand the role of the urothelium in the prevention and treatment of IC. – Key concepts in the physical examination of the IC patient – Understand the concept of multimodal therapy for the treatment of IC. Objectives • In this lecture, participants will learn: – Key treatments of IC • • • • • Antidepressants Gabapentin Intravesical therapy Pentosan polysulfate Neuromodulation – Sexual dysfunction in the IC patient – pathogenesis and treatment strategies Introduction • Challenge to diagnose • “Traditional” view recognizes patients with end-stage disease • A continuum--rather than a “fixed” disease • Confused with other GU or GYN disorders Definition • First reported in 1915 • NIH criteria established in 1987 – – – – characterize IC syndrome patient describe advanced disease do not define IC criteria represent a small part of the IC population Interstitial Cystitis (IC) Definition • Interstitial cystitis is urgency, frequency, and pain in the absence of a defined etiology C. Lowell Parsons, MD The triad of urinary urgency, frequency, and bladder or pelvic pain in the absence of bacterial infection or other definable pathology is the definition of interstitial cystitis Grannum Sant, MD “Better” Definitions • Clinical syndrome • Gradually progressive • Time line concept: – – – – 20’s: 30’s: 40’s: 60’s: mild, intermittent urgency with UTI urethral syndrome (persistent -Cx) meets NIH criteria for IC severe, constant symptoms c/w IC Clinical Picture of IC Urgency Pelvic Frequency Pain ± Incontinence • Urgency, frequency, nocturia, chronic pelvic pain (CPP) • Pain associated with sexual intimacy • +/- incontinence • Negative culture and sensitivity 1. Parsons CL. Epidemiology • Affects 2.5 million women in US • Significant number of men affected • Studies: – Finnish: incidence 1.2 cases/100,000 people • prevalence of 10-11/100,000 – Held: 44,000 cases in US; prevalence of 450,000 cases – May only reflect end-stage disease Epidemiology • More recent studies – 284 UCSD Female MS attending lectures – All filled out PUF questionnaire • 8 items • symptom, bother and total score – pelvic pain – urgency – frequency – 24% had scores > 10 Parsons, et al Urol 2002 Increasingly a Concern in Women • Estimated prevalence of self-reported IC in women is 1.5 million1 • IC is often misdiagnosed or underdiagnosed – 38% of women scheduled for laparoscopy for suspected endometriosis were cystoscopically confirmed to have IC2 • IC may be a common cause of Chronic Pelvic Pain (CPP) – 80% to 85% of women with CPP of unidentified etiology shown to have pain of bladder origin3 1. Curhan GC et al. J Urol. 1999;161:549-552. 2. Clemons JL et al. 2002;100:337-341. 3. Parsons CL et al. Obstet Gynecol. 2001;98:127-132. Possible Presentations Refractory Patients New Patients Recurrent UTI Symptoms Overactive Bladder Treatment Failures Consider IC Failed Endometriosis Therapy Nonbacterial Prostatitis 1. Parsons CL et al. Female Patient. May 2002(suppl):12-17. 2. Chung MK et al. JSLS. 2002;6:311-314. 3. Miller JL et al. Urology. 1995;45:587-590. • Urgency • Frequency • Pain – Dyspareunia Diagnostic considerations for the Primary Care Physician • For patients with: – – – – – urgency frequency dysuria painful with sexual intercourse negative urine cultures and urine cytologies SUSPECT INTERSITIAL CYSTITIS Physical Examination • Females – anterior vaginal wall tenderness – suprapubic tenderness – pelvic floor dysfunction • Males – suprapubic tenderness – sphincter spasm – tender rectal examination IC Evaluation Tools for the Primary Care Physician • Routine testing for the PCP – – – – urine analysis urine culture urine cytology voiding diary • Additional testing to be undertaken by the urologist – cystourethroscopy and urodynamics – KCL testing Voids per day • Statistics (mean) – Normal population: 6.5times/day – IC population: 16.5 times/day Anesthetic Bladder Capacity • Normal people: 1100 cc • IC patients: 575 cc Clinical Approach to IC: A Primer for the Primary Care Physician Male Female • History – ICSI – PUF • History – ICSI – CPSI – PUF • Physical exam • Physical exam • Urinalysis and/or culture • Urinalysis and/or culture • Elective tests • Elective tests – PPMT – Potassium sensitivity test – Cystoscopy and hydrodistention – Cystometrogram – Urine for cytology – Potassium sensitivity test – Cystoscopy and hydrodistention – Cystometrogram – Urine for cytology 1. ICSI = Interstitial Cystitis Symptom Index. PUF = Pelvic Pain and Post-Prostate Massa Pathogenesis • • • • • Vascular insufficiency Epithelial leak Role of Urinary Potassium Neural Up-regulation Mast Cells Epithelial Leak • Leak --> impaired migration of solutes across epithelium • “Leak assay” studies (75% + in IC) • Potassium sensitivity test + in 90% – suggest leaky epithelium – may suggest neurological inflammatory component Role of Urinary Potassium • Principle toxic substance in urine is potassium • Toxic to human cells • Urine concentration 75 mEq/L • Levels > 15 mEq/L depolarize sensory nerves and muscle Role of Urinary Potassium • Effects of excessive K+ back diffusion: – – – – – vascular destruction lymphatic destruction sensory nerve & muscle depolarization up-regulation of mast cells induction of substance P and up-regulation of pain fibers – disease progression Potassium Sensitivity May Be a Good Predictor of IC • Detects abnormal bladder epithelial permeability • Positive in 70% to 90% of IC patients • 81% of gynecologic patients with pelvic pain had increased potassium sensitivity 1. Parsons CL et al. J :1054-1057. Role of Urinary Potassium • Sodium chloride instillation does not cause symptoms • Conclusion: – individual potassium sensitivity: • useful diagnostic tool for IC • useful even in patients with mild symptoms • useful when one is unsure of the diagnosis Neural Up-regulation • Up-regulation of sensory nerves in the bladder • Seen in severe forms of IC • Difficult to treat • Can persist after treatment of epithelial defect Mast Cells • Role not fully understood • Present in IC and non-IC bladders • Causative or secondary role in IC? – Cause: degranulate & produce symptoms – Secondary: response to epithelial leak • Interact with sensory nerves & release neurotransmitters that activate pain Glycosaminoglycan (GAG) Layer in IC • GAG, a mucoprotein, is a component of bladder epithelium • GAG may be essential for bladder protection – Irritants and toxins in urine – Bacterial adherence • GAG deficiency may result in pathologic changes associated with IC – Permeability of urothelium – Inflammatory/allergic response Lilly JD, Parsons CL.;171:493-496. Vicious Cycle of IC Bladder Insult More Injury Epithelial Layer Dysfunction Mast Cell Activation and Histamine Release Potassium Leak into Interstitium Activation of C-fibers and Release of Substance P Principles of Treatment--Multimodal • Dietary guidelines • Stabilize the urothelium – pentosan polysulfate • Modulate neural activity – Tricyclic antidepressants like amitriptyline, gabapentin • Stabilize mast cells – Antihistamines, ex. Hydroxyzine • Stabilize the pelvic floor – sacral neuromodulation Pentosan Polysulfate • Mechanism: re-establish GAG layer function and decrease K+ leak • The only FDA-approved oral therapy proven effective for IC pain or discomfort • • • • Reduces painful symptoms long-term Dose: 100 mg TID (200 mg BID) Full effect takes up to 6 months Side effects: headache, GI upset, hair loss Antihistamines • Role: blockade of mast cell release of histamine • Dose: 25 mg to 75 mg qHS • Useful: – allergy sufferers (spring/fall) • Adverse: sedative properties Antidepressants • Role: decrease neural pain, decrease urgency and frequency (Ach effect) • Dose: 25 mg to 100 mg qHS amitriptyline • Some patients respond to lower doses (10 mg) • SSRI can also be considered (watch for drug-induced FSD Gabapentin • Role: inhibit neural up-regulation and neurogenic spinal cord inflammation • Use: chronic unrelenting pain • Dose: 300 mg to 2400 mg/day • Side effects: sedation • Advise: careful dose titration to balance sedative properties Intravesical Agents • Dimethyl Sulfoxide (DMSO) – Principle FDA approved intravesical agent – Instilled once weekly for at least 6 weeks – Cocktails: DMSO, sodium bicarbonate, heparin, triamcinolone, bupivicaine – 50% objective response rate Sacral Neuromodulation • Rationale – Disrupt afferent inputs to the bladder and pelvic floor that cause pathologic voiding – Specifically help regulate • capsaicin-sensitive C-afferent neurons – originate from sacral parasympathetic plexus – may relieve pelvic pain/muscle spasm • neural input through the pelvic nerve – may aid in detrusor contraction Sacral Neuromodulation • Goals of sacral neuromodulation Therapy – – – – Improve pelvic pain Improve urinary frequency Improve voided volumes Improve overall symptom scores • IC Symptom Index • Chronic Prostatitis Symptom Index Sacral Neuromodulation • Potential uses of sacral neuromodulation – Refractory urinary urge incontinence – Non-obstructive urinary retention – Refractory urinary urgency and frequency • Interstitial Cystitis Sacral Neuromodulation Current Literature • Refractory Urgency/Frequency (IC) Comiter C. – 25 patients, prospective study – Mean age 47 years – Trial of sacral nerve stimulation • • • • 50% improvement in frequency 50% improvement in nocturia 50% improvement in voided volume 50% improvement in pain – 17/25 qualified for permanent implant Sacral Neuromodulation Current Literature • Prospective study for refractory IC – Mean follow up: 14 months – Parameters: • • • • • Daytime frequency: 17 ---> 8.7 voids (p<0.01) Nocturia: 4.5 ---> 1.1 voids (p<0.01) Mean Voided Volume: 111 cc ---> 264 cc (p<0.01) Pain (1-10 scale): 5.8/10 to 1.6/10 (p<0.01) IC Symptom Index: 16.5 ---> 6.8 (p<0.01) Sacral Neuromodulation Current Literature • Prospective study for refractory IC – 16/17 (94%) had improvement in all parameters at last follow up • Conclusions – Sacral neuromodulation is safe and effective treatment of dysfunctional voiding/pelvic pain – Useful treatment for refractory IC symptoms Comiter CV. J Urol 2003 Apr;169(4):1369-73. Sacral Neuromodulation Current Literature • West Virginia University Hospital Experience – Collaborative model (Pain Treatment Center and Urology) – All patients evaluated with cystoscopy and urodynamics prior to test stimulation – 2 stage approach (test stimulation -> permanent implant Sacral Neuromodulation Current Literature • West Virginia University Hospital Experience – To date: • 210 test stimulations • 195 permanent implants – 80 implants have refractory urgency/frequency (IC) • Mean age 51 years • Mean follow up is 2 year (longest out is 3 years) • All with improvement in symptoms and voided volume as well as decline in pelvic pain/bladder spasm Zaslau S, et al. West Virginia Medical Journal, August, 2003 Sexual Problems Affecting the IC Patient • Pain associated with intercourse – Entry dyspareunia – Deep dyspareunia Entry Dyspareunia • “Pain at the opening” – Atrophic vaginitis • post menopausal women • estrogen loss • Tx: topical or oral estrogen replacement – Vaginitis • infectious (fungal) • Tx: oral or topical antifungal agents Entry Dyspareunia • Herpes vulvitis – must rule out other causes first! • Vulvodynia – vulvar pain of unknown cause – “feels like dragging sandpaper thru open wound” • Infectious vulvitis – glandular enlargement; tx: antibiotics Deep Dyspareunia • Most common type of dyspareunia in IC • Sources of pain: – Vaginal infections – Vaginal dryness • estrogen loss • psychological stress Deep Dyspareunia – Bladder pain • pain in front portion of vagina • caused by penile pressure on bladder trigone – Pain from other pelvic abnormalities • • • • endometriosis ovarian diseases pelvic infections diverticulosis Deep Dyspareunia – Pain from pelvic floor muscles • most common source of pain for IC patient • pelvic floor spasm occurs in 70% of IC patients • can prevent penile insertion Vicious cycle of muscle spasm 1. SPASM OF PELVIC MUSCLES 2. FEAR OF PAIN WITH PENETRATION PENILE PENETRATION 3. MORE MUSCLE TIGHTENING 4. PENIS PENETRATES INTO SPASTIC, TENDER MUSCLES 5. FURTHER TIGHTENING OF MUSCLES IC and Female Sexual Dysfunction (FSD) • 100 patients with IC • FSFI administered – Assess 6 domains of sexual function • • • • • • Desire Arousal Orgasm Lubrication Satisfaction Pain IC and FSD • Results: – Mean age 39 years – Impairment in all domains “50-75% of the time” • Conclusions – FSD in IC involves more than pelvic pain Zaslau, S et al FSFF, Vancouver, BC 2002 FSD in IC: 1st 400 Patients • 400 IC patients • FSFI administered on line at IC-Network • Compared to two groups – Controls (131) – Female sexual arousal disorder (129) FSD in IC 1st 400 Patients • Results – Statistically significant decrease in all domains when compared to controls – Stastically significant decrease in all domains when compared to Arousal Disorder Group – Lowest scores: pain Zaslau, et al AUA 2003, Chicago, IL. Conclusions: IC and FSD • Global sexual dysfunction affecting all domains • May be age related and progressive • Pain domain has lowest scores • Treatment is multimodal and may involve counseling, sex therapy and physical therapy General Treatment Principles • Talk to your partner – create “game plan” to deal with partner needs – role for physician, social worker, sex therapist • Don’t focus only on penetration – Shift major focus to foreplay, full body massage, deep kissing, fondling, oral-genital contact General Treatment Principles • Watch out for medication effects on orgasm – medications can cause fatigue and/or loss of sexual desire – antidepressants impair orgasm • Go slow – forget the terrible memories – Relax to prevent pelvic muscle spasm – Go slow with insertion and thrusting General Treatment Principles • Lots of lubrication – aids in penetration – especially helpful in vulvodynia • Be in control – goes along with going slow – let the patient call the shots – communicate! General Treatment Principles • Find the right position – There is no “perfect position” – Goal: minimize vaginal tenderness, adjust vault-penis angle and partner weight – Missionary: most discomfort for female partner (penile-->bladder base pressure) – Female superior: more control for IC female General Treatment Principles • Go one step at a time – – – – Step-wise approach for vaginal penetration First goal: NOT penis in vagina = orgasm! Don’t focus on vaginal entry initially Instead: superficial penetration and maximize foreplay General Treatment Principles • Avoid intercourse during flares – Flare can be related to menses – Increased urinary frequency and pelvic pain = flare – Focus away from intercourse and onto foreplay! • Take advantage of remissions – take things slow; “roll with the punches” General Treatment Principles • Take a warm bath after sex – can relax pelvic floor muscles – can be therapeutic after sex – however, warmth can be irritating! • Avoid urinary tract infections – void before and after sexual relations • Avoid use of diaphragm – can increase UTI and pelvic pain/irritation General Treatment Principles • Use vaginal dilators/biofeedback – – – – can relax vaginal vault patient in total control of insertion step-wise treatment strategy minimizes anxiety General Treatment Principles • Read and learn more about IC – Interstitial Cystitis Association (www.ichelp.org) – Interstitial Cystitis Network (www.ic-network.com) Summary • Interrelationships between conditions: – Overactive Bladder • No bacteriuria • No bladder pain – Urinary Tract Infection • Bacteriuria and bladder pain – Interstitial Cystitis • Bladder pain and no bacteriuria Summary (continued) • The prevalence of IC is much higher than previously estimated • IC should be considered in patients who have failed standard therapy for endometriosis (prior to hysterectomy), OAB, or have symptoms of recurrent/chronic UTI and do not improve on antibiotics • Increase awareness of IC as part of CPPS differential diagnosis • Symptoms of CP/CPPS appear to be similar to IC • Treatment of IC is multimodal (pentosan polysulfate, antidepressants, antihistamines, role for sacral neuromodulation in treatment failures) *NBP = non-bacterial References – 1 • Peters KM, Killinger KA, Carrico DJ, Ibrahim IA, Diokno AC, and Graziottin A: Sexual Function and Sexual Distress in Women with Interstitial Cystitis: A Case Control Study. Urology. 2007; 70(3): 543-547. • Zaslau S, Triggs J, Morgan L, Osborne J, Subit M, Riggs D: “Characterization of Female Sexual Dysfunction in Patients with Interstitial Cystitis.” Presented at the American Urological Society Meeting, Chicago, IL, April 27, 2003. References - 2 • Zaslau S, Subit MJ, Mohseni HF, Riggs D, Jackson B, Kandzari S: “Sexual Dysfunction in Patients with Interstitial Cystitis.” Presented at the American Urogynecology Meeting, Hollywood, FL, September 12, 2003. • Zaslau S, Subit MJ, Mohseni HF, Riggs D, Jackson B, Kandzari S. “Sexual Dysfunction in Patients with Interstitial Cystitis: Initial Analysis of Under 40 Cohort.” Presented at the Mid-Atlantic Section of the American Urological Society Meeting, Boca Raton, FL, October 2629, 2003. References - 3 • • • Zaslau S: Blueprints in Urology, 1st ed. Boston, MA: Blackwell Science, Inc., 2004. Zaslau S: SOAP Notes in Urology, 1st ed. Baltimore, MD: Lippincott Williams and Wilkins, Inc., 2006. Messing EM. Interstitial cystitis and related syndromes. In: Campbell’s Urology, 6th Edition. Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr (eds). Philadelphia: WB Saunders Co., Volume 1, Chapter 24, pp. 982-1005, 1992.